Keywords: SGLT2 مهار کننده; SGLT2 inhibitors; Insulin; type 2 diabetes; individualization; inhibiteurs du SGLT2; insuline; diabète de type 2; individualisation;
مقالات ISI SGLT2 مهار کننده (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: SGLT2 مهار کننده; Ertugliflozin; l-arabinose; Dihydroxylation; Aldol condensation; SGLT2 inhibitors;
Keywords: SGLT2 مهار کننده; blood pressure; diabetic kidney disease; DPP-4 inhibitors; GLP-1R agonists; glycemia; SGLT2 inhibitors; pression artérielle; néphropathie diabétique; inhibiteurs de la DPP-4; agonistes des récepteurs GLP-1; glycémie; inhibiteurs du SGLT2;
Keywords: SGLT2 مهار کننده; Diabetes type 2; SGLT2 inhibitors; Cardiovascular disease; Kidney disease; Safety; Amputation; Fracture; Systematic review; Randomised controlled trials; AKI; Acute kidney impairment; CVD; Cardiovascular disease; MACE; Major macrovascular event; SGLT2; So
Keywords: SGLT2 مهار کننده; SGLT2 inhibitors; Type 2 diabetes; Moderate renal function impairment; Meta-analysis;
Keywords: SGLT2 مهار کننده; baseline characteristics; DPP-4 inhibitors; personalized medicine; SGLT2 inhibitors; type 2 diabetes;
Keywords: SGLT2 مهار کننده; Type 1 diabetes; Type 2 diabetes; Diabetic nephropathy; DPP-4 inhibitors; SGLT2 inhibitors; Hyperfiltration;
Keywords: SGLT2 مهار کننده; Type 2 diabetes; East Asians; Visceral adiposity; SGLT2 inhibitors; Cardiovascular outcome; Renoprotection;
Keywords: SGLT2 مهار کننده; SGLT2 Inhibitors; Dapagliflozin; Canagliflozin; Empagliflozin; CANVAS; CREDENCE; DECLARE-TIMI 58; Cardiovascular outcomes; Nonglycemic benefit of SGLT2 inhibitors;
Keywords: SGLT2 مهار کننده; Diabetes mellitus; Metformin; TZDs; Incretins; DPP-4 inhibitors; SGLT2 inhibitors;
Keywords: SGLT2 مهار کننده; Diabetes mellitus; GLP-1 receptor agonists; DPP-4 inhibitors; SGLT2 inhibitors; Insulin;
Keywords: SGLT2 مهار کننده; canagliflozin; diabetes; glycemic control; HbA1c; Medicare; SGLT2 inhibitors;
Keywords: SGLT2 مهار کننده; T2DM; glucose-lowering therapies; hypoglycaemia; incretin therapies; SGLT2 inhibitors; insulin;
Keywords: SGLT2 مهار کننده; Diabetes mellitus; Cancer risk; Insulin; Antidiabetic drugs; ATP; adenosine triphosphate; BMI; body mass index; CI; confidence interval; DDDs; defined daily doses; DNA; deoxyribonucleic acid; DPP-4 inhibitors; dipeptidyl peptidase-4 inhibitors; Egr-1; ear
Keywords: SGLT2 مهار کننده; Sodium glucose cotransporter 2; SGLT2; SGLT2 inhibitors; Type 2 diabetes; Antihyperglycemic agents;
Keywords: SGLT2 مهار کننده; SGLT2 inhibitors; blood pressure; diabetes mellitus; meta-analysis;
Keywords: SGLT2 مهار کننده; Diabetes; Genital infections; SGLT2 inhibitors; Review; Urinary infectionsUTI, urinary tract infection; CFU, colony-forming unit
Production of acetophenone C-glucosides using an engineered C-glycosyltransferase in Escherichia coli
Keywords: SGLT2 مهار کننده; C-Glycosyltransferase; Whole-cell bioconversion; Mono-C-glucosides; Bis-C-glucosides; SGLT2 inhibitors;
SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms
Keywords: SGLT2 مهار کننده; SGLT2 inhibitors; Electrolytes; Magnesium; Potassium; Phosphate; Cardiovascular disease;
Insuffisance cardiaque et diabète : la nouvelle épidémie sous-estimée, mal connue, qui ne peut être ignorée plus longtemps
Keywords: SGLT2 مهار کننده; Diabète; insuffisance cardiaque; physiopathologie; dépistage; examens biologiques; échographie cardiaque; traitement; coûts; gliflozines; Diabetes; heart failure; pathophysiology; screening; biological tests; echocardiography; treatment; costs; SGLT2
Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy
Keywords: SGLT2 مهار کننده; ABP; arterial blood pressure; ACE; angiotensin converting enzyme; AGEs; advanced glycation end products; ARB; angiotensin receptor blocker; BUN; blood urea nitrogen; Cr Cl; creatinine clearance; DN; diabetic nephropathy; GSH-Px; glutathione peroxidase; Hb
The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents
Keywords: SGLT2 مهار کننده; Sulfonylureas; Type 2 diabetes; DPP4 inhibitors; Gliclazide; Glipizide; Glibenclamide/glyburide; Glimepiride; SGLT2 inhibitors;
Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
Keywords: SGLT2 مهار کننده; Cardiovascular disease; GLP-1 receptor agonists; Heart failure; Mortality; SGLT2 inhibitors; Type 2 diabetes;
Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program
Keywords: SGLT2 مهار کننده; SGLT2 inhibitors; Risk of infections; Australia;
Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells
Keywords: SGLT2 مهار کننده; Alpha cells; Glucagon; SGLT1; SGLT2 inhibitors;
Sécurité cardiovasculaire des agonistes du récepteur du glucagon-like peptide-1 et des inhibiteurs du co-transporteur sodium-glucose de type 2 : focus sur les résultats des grands essais d'intervention
Keywords: SGLT2 مهار کننده; Agonistes du récepteur du GLP-1; Inhibiteurs de SGLT2; Diabète de type 2; Ãvénements cardiovasculaires; Essais randomisés et contrôlés; GLP-1 receptor agonists; SGLT2 inhibitors; Type 2 diabetes; Cardiovascular events; Randomized controlled trials;
Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels
Keywords: SGLT2 مهار کننده; Dapagliflozin; Dyslipidemia; Type II diabetes mellitus; SGLT2 inhibitors; Cardiovascular;
Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database
Keywords: SGLT2 مهار کننده; Diabetes; Renal failure; SGLT2 inhibitors; Adverse effects;
Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus
Keywords: SGLT2 مهار کننده; SGLT2 inhibitors; Dapagliflozin; Canagliflozin; Empagliflozin; Metformin; Type 2 diabetes mellitus; HbA1c;
Resolving the KgA1c paradox in the management of type 2 diabetes mellitus
Keywords: SGLT2 مهار کننده; Canagliflozin; Dapagliflozin; Empagliflozin; KgA1c paradox; Overweight; SGLT2 inhibitors; Type 2 diabetes mellitus;
Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol
Keywords: SGLT2 مهار کننده; Diabetes; Canagliflozin; Invokana; SGLT2 inhibitors; Anhydroglucitol; Mathematical model;
Les acidocétoses diabétiques atypiques
Keywords: SGLT2 مهار کننده; Acidocétose diabétique; diabète de type 1; diabète de type 2; inhibiteurs des SGLT-2; alcool; antipsychotiques atypiques; Diabetic ketoacidosis; type 1 diabetes; type 2 diabetes; SGLT2 inhibitors; alcohol; atypical antipsychotics;
SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis
Keywords: SGLT2 مهار کننده; diabetic ketoacidosis; euglycemia; insulin; SGLT2 inhibitors;
Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes
Keywords: SGLT2 مهار کننده; Tetrahydroisoquinoline-C-aryl glucosides; SGLT2 inhibitors; Type 2 diabetes; Tetrahydroisoquinoline
Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places
Keywords: SGLT2 مهار کننده; Empagliflozin; SGLT2 inhibitors; Cardio-protection; Type 2 diabetes;
Inhibiteurs de SGLT2 dans le diabète de type 1 : vraie perspective ou fausse bonne idée ?
Keywords: SGLT2 مهار کننده; Inhibiteurs de SGLT2; Diabète de type 1; Stratégie thérapeutique; Hyperfiltration glomérulaire; Néphroprotection; SGLT2 inhibitors; Type 1 diabetes; Treatment strategy; Glomerular hyperfiltration; Renal protection;
Identification of phlorizin binding domains in sodium-glucose cotransporter family: SGLT1 as a unique model system
Keywords: SGLT2 مهار کننده; Sodium glucose cotransporter SGLT1; SGLT2 inhibitors; C-terminal loop 13; Modeling; SGLT inhibition; Phlorizin binding domain
Les inhibiteurs de SGLT2 : pour quels patients ? Quelle place dans la stratégie thérapeutique ?
Keywords: SGLT2 مهار کننده; Diabète de type 2; Inhibiteurs de SGLT2; Glycosurie; Dapaglifozine; Canagliflozine; Empaglifozine; Type 2 diabetes; SGLT2 inhibitors; Glucosuria; Dapaglifozin; Canagliflozin; Empaglifozin;
Inhibiteurs du SGLT2. Résultats des études cliniques de phase III : Effets glycémiques, pondéraux et tensionnels
Keywords: SGLT2 مهار کننده; Antidiabétiques oraux; Inhibiteurs de SGLT2; HbA1c; Effet additif; Durabilité; Poids; Pression artérielle; Oral antidiabetic agents; SGLT2 inhibitors; HbA1c; Additive effect; Durability; Weight; Blood pressure;
Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1,2,3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors
Keywords: SGLT2 مهار کننده; Triazole; Rhamnose; Diabetes; Click chemistry; SGLT2 inhibitors;
SGLT2 inhibitors in the treatment of type 2 diabetes
Keywords: SGLT2 مهار کننده; Type 2 diabetes; Glucose reabsorption; SGLT2 inhibitors; Dapagliflozin; Canagliflozin; EmpagliflozinHbA1c, hemoglobin A1c; FRG, familial renal glucosuria; GLUT, glucose transporter; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose;
Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2
Keywords: SGLT2 مهار کننده; Dapagliflozin; Occupational exposure limit; Pharmacokinetics; SGLT2 inhibitors; Urinary glucose excretion;
Diabetes Mellitus in the Next Decade: Novel Pipeline Medications to Treat Hyperglycemia
Keywords: SGLT2 مهار کننده; Diabetes; Novel therapies; Insulin analogs; SGLT2 inhibitors; GPR 40 agonists;
Le rôle du rein dans l'homéostasie du glucose
Keywords: SGLT2 مهار کننده; Production de glucose; néoglucogenèse; utilisation du glucose; réabsorption du glucose; co-transporteurs de glucose (SGLT1 et SGLT2); transporteurs de glucose de diffusion facilitée (GLUT1 et GLUT2); inhibiteurs de SGLT2; Glucose production; gluconeog
Need for better diabetes treatment for improved renal outcome
Keywords: SGLT2 مهار کننده; antidiabetic drugs; diabetic nephropathy; SGLT2 inhibitors;
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
Keywords: SGLT2 مهار کننده; diabetes mellitus, type 2; glucosuria; SGLT2 inhibitors; sodium-glucose transport proteins;
Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study
Keywords: SGLT2 مهار کننده; dapagliflozin; hepatic impairment; pharmacokinetics; SGLT2 inhibitors; special populations
Inhibiteurs du cotransporteur sodium-glucose de type 2 (SGLT2) : une nouvelle approche thérapeutique pour le diabète de type 2 ?
Keywords: SGLT2 مهار کننده; Diabète de type 2; excrétion rénale du glucose; inhibiteurs du cotransporteur sodium-glucose de type 2 (SGLT2); thérapeutique; Type 2 diabetes mellitus; renal glucose excretion; SGLT2 inhibitors; therapeutics;